Cigarette smoking, smoking cessation, and overactive bladder (OAB): a cross-sectional research of NHANES 2011 to 2018 Authors: Weibo Wang, Supeng Tai, Xi Cheng, Junyue Tao, Lexing Yang, Jun Zhou Published: 2025 ABSTRACT AbstractBackgroundOveractive bladder (OAB) is a prevalent lower urinary tract syndrome (LUTS) that adversely affects quality of life. Despite its increasing prevalence, particularly among the aging population, the pathophysiological mechanisms of OAB remain unelucidated. Cigarette smoking has been implicated in exacerbating certain LUTS. However, the relationship between smoking status and OAB, especially in terms of smoking cessation, remains underexplored.MethodsThis cross-sectional study was conducted using data from National Health and Nutrition Examination Survey (NHANES) spanning 2011–2018, encompassing 16,789 participants aged 20 years and older. We investigated the associations of cigarette smoking and smoking cessation with OAB. Weighted logistic regression models were employed to estimate the odds ratios (ORs) for OAB and Overactive Bladder Symptom Score (OABSS) scores, adjusted for relevant sociodemographic, lifestyle and health risk factors.ResultsThe analysis indicated that current smokers exhibited a higher risk of OAB (OR = 1.24; 95% CI: 1.04–1.47, P = 0.018) and an increased OABSS score (OR = 1.17, 95% CI: 1.05–1.31, P = 0.006) compared to never smokers. Furthermore, a dose-response relationship was observed between daily cigarette consumption and OAB risk, with heavy smokers demonstrating a significantly increased risk (OR = 1.95, 95% CI: 1.23–3.10, P = 0.006). Ex-smokers, did not significantly elevate the risk compared to never smokers (OR = 1.03,95% CI: 0.82–1.28, P = 0.808), but were significantly associated with a higher OABSS score among who without OAB (OR = 1.14, 95% CI: 1.02–1.28, P = 0.024).ConclusionsThe study revealed that cigarette smoking was associated with a higher risk of OAB and a greater OAB-related symptom burden. Although the differences were not statistically significant, ex-smokers tended to show lower OAB risk than current smokers but still reported more severe symptoms than never smokers. These findings suggest that smoking history, including both current and past smoking, is relevant for the prevention and management of OAB and support the promotion of smoking cessation in this context. More rigorous prospective cohort studies are warranted to further clarify these associations and their potential causal pathways.Supplementary InformationThe online version contains supplementary material available at 10.1186/s12889-025-25984-z.Keywords: Cigarette smoking, Smoking cessation, Overactive bladder, OABSS, NHANES Introduction Overactive bladder (OAB) is a commonly encountered lower urinary tract syndrome (LUTS) in clinical practice. In 2002, the International Continence Society defined OAB as “urgency, with or without urgency urinary incontinence (UUI), usually accompanied by increased daytime frequency and nocturia” [1]. These symptoms impair bladder storage function and significantly hinder daily functioning in patients. Epidemiological studies have consistently shown that OAB is prevalent worldwide, with rates tending to rise with age, thereby adding medical pressure to healthcare systems [2]. Although OAB was once regarded as more common in women, recent evidence suggests an increasing burden among men as well. Among American males, the prevalence increased slightly from 11.3% in 2005–2008 to 11.7% in 2009–2014, and significantly to 14.5% in 2015–2020 [3]. Evidence also suggests that the onset age of OAB is trending younger, potentially related to lifestyle, dietary habits, hobbies, and work stress, among other factors [4]. As a syndrome defined by clinical symptoms, the pathogenesis of OAB is not fully understood, with recent studies pointing to neural dysfunction and bladder wall abnormalities as potential contributors [5, 6]. Therefore, current treatments for OAB primarily target symptom relief rather than addressing the underlying cause, which imposes a significant medical burden on society [7]. Given the high prevalence and poor prognosis of OAB, elucidating its etiology and implementing targeted interventions are of paramount importance for public health and public policy. The effects of cigarette smoking on human health are multifaceted and profound, impacting various systems and organs [8–11]. Several studies have indicated that smoking may exacerbate certain LUTS by disrupting nerve innervation, altering sex hormone levels, and damaging bladder endothelial cells [12–14], which influence the storage, voiding, and post-voiding phases simultaneously. However, certain research pointed out that smoking may alleviate nocturia symptoms by modulating the circadian rhythm of urine production [15]. To date, systematic studies specifically examining the association of smoking status with OAB remain sparse, with no consensus on the pathophysiological mechanisms. The prevailing view suggests that the onset and progression of OAB involve detrusor overactivity, which is regulated by both the central and peripheral nervous systems [16]. Consequently, some studies hypothesized that the higher prevalence of OAB among smokers may be attributed to the impact of nicotine on bladder function and neural regulation [13]. Current findings of the association between smoking and OAB are superficial and limited in scope. Previous studies have overly emphasized the impact of gender and age on OAB, often selecting participants from specific gender or age groups. While this approach helps mitigate biases arising from anatomical and behavioral differences, it inevitably limits the generalizability of the findings to the broader population [17–19]. Furthermore, these studies did not quantify OAB symptoms, merely categorizing outcomes as either present or absent, which led to limitations in the conclusions drawn. This highlights the need for validation and further investigation of existing findings. Benefiting from its large sample size and systematic individual health assessments, the National Health and Nutrition Examination Survey (NHANES) database enabled us to ascertain the smoking status. Study participants were partitioned into never smokers, current smokers, or ex-smokers who had quit smoking, and we evaluated the odds ratios (ORs) for OAB across smoking status. An in-depth analysis of the dose-response relationship between daily cigarette consumption and OAB among current smokers was conducted, which was further validated through subgroup analyses. Additionally, we placed particular emphasis on ex-smokers and provided guidance for the early prevention and the prognosis improvement of OAB. Materials and methods Study design and participants population The NHANES database is a national survey project led by the Centers for Disease Control and Prevention (CDC), designed to assess the health and nutritional status of the U.S. population. The project includes household interviews, mobile examination center assessments, and laboratory tests, with all data collected using a complex, multistage probability sampling design. To correct for nonresponse rates and ensure the sample is nationally representative, data analyses were weighted. Considering NHANES data are released in cycles, we utilized data from the four most recent cycles spanning 2011–2018, which included 9,756 participants in 2011–2012, 10,175 in 2013–2014, 9,971 in 2015–2016, and 9,254 in 2017–2018, to ensure the accuracy and reliability of the results. After applying exclusion criteria, this study included a total of 16,789 adults aged 20 years and above who provided comprehensive data on smoking status and OAB diagnosis. Detailed information on the study design and specific inclusion and exclusion criteria can be found in Fig. 1. All data were obtained from the public portion of the NHANES database, so no additional ethical approval was required for this study. Flowchart of Study Design and Participant Exclusion and Inclusion Criteria. NHANES, National Health and Nutrition Examination Survey; OAB, overactive bladder Exposure variable In our study, smoking status and daily cigarette consumption were main exposure variables, with data collected by a standard questionnaire in household interviews. Smoking status was determined by the question, “Have you smoked at least 100 cigarettes in your entire life?” If the answer was “no,” participants were considered as non-smokers; those who answered “yes” were further classified as ex-smokers or current smokers through the question, “Do you now smoke cigarettes?” Participants who answered “every day” or “some days” were classified as current smokers, while those who answered “not at all” were classified as ex-smokers. Daily cigarette consumption referred to the average number of cigarettes smoked per day and was measured by questions, “How many of the past 30 days did you smoke a cigarette?” and “During the past 30 days, on the days that you smoked, about how many cigarettes did you smoke per day?” Current smokers were categorized into four groups according to their average daily cigarette consumption, using cut-off values at 3, 9, and 15 cigarettes per day: Light Smokers (≤ 3 cigarettes/day), Low-Moderate Smokers (> 3 to ≤ 9 cigarettes/day), Moderate-High Smokers (> 9 to ≤ 15 cigarettes/day), and Heavy Smokers (> 15 cigarettes/day). These cut-off points were chosen exploratorily based on visual inspection of the distribution of daily cigarette consumption and divided the population into approximately four groups. Outcome variable OAB was the primary outcome variable and was characterized by UUI and nocturia, with diagnostic information obtained from household interviews and collected through questionnaires. UUI was diagnosed with the question, “During the past 12 months, have you leaked or lost control of even a small amount of urine with an urge or pressure to urinate and you couldn’t get to the toilet fast enough?“, and the question “How frequently does this occur?” further measured the frequency. The symptom and frequency of nocturia were assessed with the question, “During the past 30 days, how many times per night did you most typically get up to urinate, from the time you went to bed at night until the time you got up in the morning?” The quantitative standard for OAB was determined through the questionnaire, Overactive Bladder Symptom Score (OABSS) questionnaire. As demonstrated in Table 1, the OABSS score for each participant was measured as the sum of the UUI score and the nocturia score, ranging from 0 to 6, representing the severity of symptoms. An individual score of 3 or higher was used as the diagnostic criterion for OAB [20]. Table 1Criteria for conversion of symptom frequencies recorded in NHANES and OABSS scores. NHANES, National health and nutrition examination Survey; OABSS, overactive bladder symptom Score; UUI, urgency urinary incontinenceAccording to NHANES scoreAccording to OABSS scoreUUI frequencyUUI score Never0 Less than once a month1 A few times a month1 A few times a week2 Every day and/or night3Nocturia frequencyNocturia score 00 11 22 3 or more3 Criteria for conversion of symptom frequencies recorded in NHANES and OABSS scores. NHANES, National health and nutrition examination Survey; OABSS, overactive bladder symptom Score; UUI, urgency urinary incontinence Covariates Two categories of covariates, the sociodemographic factors, and the lifestyle and health risk factors were included. Data on sociodemographic factors were obtained through household interviews and included the following: age (20–39, 40–59, 60–79, ≥ 80), gender (male, female), ethnicity (Mexican American, other Hispanic, non-Hispanic White, non-Hispanic Black, other/multiracial), education level (less than high school, high school graduate, college or higher), marital status (married, widowed, divorced, separated, never married, living with a partner), and poverty-to-income ratio (PIR) (< 1, 1–3.5.5, ≥ 3.5). As for lifestyle and health risk factors, body mass index (BMI) and waist circumference were collected by health technicians at mobile examination centers (MEC) using standardized procedures. BMI was calculated as weight (kg) divided by the square of height (m²). Histories of hypertension, high cholesterol, diabetes and sleep disorder were self-reported by participants in household interviews. Physical activity level was assessed using metabolic equivalents (METs) from the National Center for Health Statistics (NCHS) questionnaires and expressed as total weekly MET-minutes, on the basis of which participants were categorized into four groups: low (< 1200), moderate (1200–3320), high (3320–8400), and very high (≥ 8400) [21]. Drinking history was assessed with the question, “In any one year, have you/has SP had at least 12 drinks of any type of alcoholic beverage?”, and a “yes” response was considered indicative of a habitual drinking behavior in the participants. However, drinking was failed to be assessed during the 2017–2018 cycle due to changes in the alcohol use questionnaire, so the missing data were represented by a dummy variable and incorporated into subsequent model fitting. Statistical analysis In accordance with the NHANES database guidelines, we applied the appropriate sample weights in our statistical analysis to account for the oversampling of certain subgroups, unequal selection probabilities, and adjustments for nonresponse. For the baseline characteristics, sample size and weighted percentages were used to describe categorical variables, while weighted means and standard errors (SE) were used to describe continuous variables. Survey-weighted analysis of variance (ANOVA) was utilized to evaluate the statistical differences of continuous variables and survey-weighted chi-square test was employed for categorical variables. In the correlation analysis, univariate and multivariate logistic regression models were employed to estimate the odds ratios (ORs) and 95% confidence intervals (CIs) for the association between smoking status and OAB risk, and ordinal logistic regression models were used for the association between smoking status and OABSS scores. To further validate the association of smoking cessation with OABSS scores, we selected participants without OAB for a sensitivity analysis. Additionally, logistic regression models were utilized to estimate the ORs and 95% CIs for the association between daily cigarette consumption and OAB risk, and a restricted cubic spline (RCS) was employed to explore the nonlinear dose-response relationship between the two. Furthermore, we performed subgroup analyses and interaction tests to validate the findings, with significance was determined by likelihood ratio tests and expressed as p-values. To ensure accuracy and rigor, all models applied the recommended survey weights and underwent two rounds of adjustments. Model 1 was a univariate analysis, Model 2 adjusted for sociodemographic factors, and Model 3 further adjusted for lifestyle and health risk factors in addition to Model 2 adjustments. All statistical analyses were conducted using R v. 4.4.0 and Stata v. 17.0, with two-sided p-values less than 0.05 considered statistically significant. Results This study included a total of 16,789 participants aged 20 years and older, representing 1,890,357,992 U.S. adults for further analysis. Among them, a total of 3,295 participants self-reported as current smokers (18.71%), 4,000 participants as ex-smokers (25.1%), and the remaining 9,494 participants identified as never smokers (56.27%). Current smokers tended to be younger, with a higher likelihood of being under the age of 60 (83.68%). They were more likely to be single, have lower educational attainment, a lower PIR, and present with both lower BMI and lower waist circumference, while being more likely to engage in intense physical activities. Ex-smokers, with a higher likelihood of being over the age of 60 (42.03%), had higher BMI and higher waist circumference and were more likely to suffer from hypertension, high cholesterol, diabetes and sleep disorders. Never smokers were more likely to be female and tended to have higher educational attainment and a higher PIR. Among all participants, the weighted mean OABSS score (SE) was 1.30 (0.02) and 3,157 participants were diagnosed with OAB (16.53%). The percentage of participants with OAB per smoking status was weighted 17.76%, 19.92%, 14.58% for current, ex- and never smokers respectively. Additionally, ex-smokers had a higher OABSS score (1.46 ± 0.04), which represented significant differences among smoking statuses (P < 0.001). Table 2 presented the detailed baseline characteristics of participants categorized by smoking status. Table 2Characteristics of study participants by categories of smoking status, weighted. PIR, poverty income ratio; BMI, body mass index; SD, standard deviation; OAB, overactive bladder; OABSS, overactive bladder symptom scoreCharacteristicsSmoking StatusTotal(n = 16,789)Never smokers(n = 9,494)Ex-smokers(n = 4,000)Current smokers(n = 3,295)P valueWeight (N)1,890,357,9921,063,671,462472,874,992353,811,542Sociodemographic FactorsAge (years)(n, %)< 0.001 20–395,707 (36.37)3,636 (40.32)766 (23.07)1,305 (42.29) 40–595,557 (36.69)3,140 (35.96)1,157 (34.80)1,260 (41.39) 60–794,645 (23.27)2,248 (20.16)1,699 (35.88)698 (15.77) ≥80880 (3.67)470 (3.56)378 (6.25)32 (0.55)Gender(n, %)< 0.001 Male8,286 (49.03)3,903 (43.12)2,462 (58.13)1,921 (54.65) Female8,503 (50.97)5,591 (56.88)1,538 (41.87)1,374 (45.35)Ethnicity(n, %)< 0.001 Mexican American2,181 (8.07)1,388 (9.34)497 (6.53)296 (6.32) Other Hispanic1,684 (5.85)1,021 (6.56)426 (5.18)237 (4.59) Non-Hispanic White6,610 (67.15)3,183 (63.24)1,925 (75.68)1,502 (67.50) Non-Hispanic Black3,721 (10.61)2,132 (11.58)693 (6.40)896 (13.31) Other/multiracial2,593 (8.32)1,770 (9.27)459 (6.21)364 (8.28)Education level(n, %)< 0.001 Less than high school3,337 (12.75)1,611 (9.847)857 (13.29)869 (20.78) High school3,780 (22.61)1,829 (18.91)964 (24.13)987 (31.74) Collage or higher9,672 (64.63)6,054 (71.25)2,179 (62.58)1,439 (47.48)Marital status(n, %)< 0.001 Married8,497 (54.80)5,061 (57.94)2,260 (60.03)1,176 (38.39) Widowed1,163 (5.16)609 (4.71)375 (6.72)179 (4.41) Divorced1,889 (10.52)842 (8.41)557 (12.96)490 (13.61) Separated565 (2.34)273 (1.90)113 (1.70)179 (4.51) Never married3,244 (18.67)2,015 (20.16)437 (11.60)792 (23.64) Living with partner1,431 (8.52)694 (6.89)258 (6.99)479 (15.43)PIR(n, %)< 0.001 <13,543 (14.21)1,768 (12.24)666 (9.834)1,109 (25.97) 1–3.5.58,099 (42.98)4,392 (40.17)2,016 (43.34)1,691 (50.93) ≥3.55,147 (42.82)3,334 (47.59)1,318 (46.82)495 (23.10)Lifestyle and Health Risk FactorsBMI (kg/m2)(mean ± SD)29.27 ± 0.1229.18 ± 0.1430.18 ± 0.1828.35 ± 0.18< 0.001Waist circumference(cm)(mean ± SD)100.13 ± 0.3098.77 ± 0.33104.23 ± 0.4698.75 ± 0.45< 0.001Hypertension(n, %)< 0.001 No hypertension10,675 (67.51)6,427 (71.69)2,108 (58.04)2,140 (67.62) Hypertension6,114 (32.49)3,067 (28.31)1,892 (41.96)1,155 (32.38)High cholesterol(n, %)< 0.001 No high cholesterol10,889 (65.71)6,447 (68.95)2,125 (54.97)2,317 (70.30) High cholesterol5,900 (34.29)3,047 (31.05)1,875 (45.03)978 (29.70)Diabetes(n, %)< 0.001 No diabetes14,519 (89.78)8,367 (91.06)3,204 (85.10)2,948 (92.18) Diabetes2,270 (10.22)1,127 (8.94)796 (14.90)347 (7.82)Sleep disorder(n, %)< 0.001 No sleep disorder12,240 (70.26)7,371 (75.79)2,683 (63.15)2,186 (63.16) Sleep disorder4,549 (29.74)2,123 (24.21)1,317 (36.85)1,109 (36.84)Physical activity level(n, %)< 0.001 Lower8,127 (43.84)4,616 (43.52)2,018 (46.23)1,493 (41.63) Moderate3,580 (24.03)2,186 (26.47)859 (23.50)535 (17.37) High2,726 (17.48)1,541 (17.35)617 (17.31)568 (18.10) Intense2,356 (14.65)1,151 (12.66)506 (12.96)699 (22.89)Drinking(n, %)< 0.001 Non-drinking3,530 (15.84)2,788 (22.19)430 (8.08)312 (7.15) Drinking9,231 (58.49)4,411 (51.63)2,570 (65.79)2,250 (69.36) Missing data4,028 (25.66)2,295 (26.18)1,000 (26.13)733 (23.49)OAB indicatorsOAB(n, %)< 0.001 No OAB13,272 (83.65)7,756 (85.42)2,961 (80.71)2,555 (82.24) OAB3,517 (16.35)1,738 (14.58)1,039 (19.29)740 (17.76)OABSS score(n, %)< 0.001 04,396 (28.93)2,697 (31.36)820 (23.66)879 (28.68) 15,646 (36.25)3,290 (36.93)1,288 (35.86)1,068 (34.72) 23,230 (18.47)1,769 (17.13)853 (21.20)608 (18.84) 32,232 (10.89)1,110 (9.80)643 (12.66)479 (11.80) 4810 (3.55)400 (3.15)250 (4.24)160 (3.82) 5287 (1.20)145 (1.05)87 (1.57)55 (1.19) 6188 (0.71)83 (0.58)59 (0.83)46 (0.95) Mean(mean ± SD)1.30 ± 0.021.22 ± 0.021.46 ± 0.041.35 ± 0.03 Characteristics of study participants by categories of smoking status, weighted. PIR, poverty income ratio; BMI, body mass index; SD, standard deviation; OAB, overactive bladder; OABSS, overactive bladder symptom score Waist circumference (cm)(mean ± SD) Table 3 presented the association between smoking status and OAB. With never-smokers as the reference group, current smokers had a higher risk of OAB (OR = 1.27, 95% CI: 1.08–1.48, P = 0.003) and a higher OABSS score(OR = 1.20, 95% CI: 1.09–1.33, P = 0.001) in the Model 1.The positive associations of current smokers with OAB (OR = 1.24, 95% CI: 1.04–1.47, P = 0.018) and the OABSS score (OR = 1.17, 95% CI: 1.05–1.31, P = 0.006) only slightly decreased in Model 3. Ex-smokers had an elevated risk of OAB (OR = 1.40, 95% CI: 1.18–1.66, P < 0.001) and a higher OABSS score (OR = 1.45, 95% CI: 1.31–1.61, P < 0.001) in Model 1 as well. However, it’s worth noting that the risk of OAB among ex-smokers was higher than that of never smokers (OR = 1.03, 95% CI: 0.82–1.28, P = 0.808) and lower than that of current smokers (OR = 0.83, 95% CI: 0.66–1.05, P = 0.116), and both associations were not statistically significant in Model 3. Additionally, the fully adjusted OR for OABSS scores among ex-smokers decreased to 1.11 (95% CI: 0.98–1.25, P = 0.093), presenting only a marginal association in Model 3. Table 3Association of smoking status with OAB and OABSS scoresOAB indicatesSmoking StatusNever smokersEx-smokersCurrent smokersOR (95% IC)P valueOR (95% IC)P valueOR (95% IC)P valueWith never smokers as the reference groupOAB Model 1a1 (Reference)1.40(1.18, 1.66)< 0.0011.27(1.08, 1.48)0.003 Model 2b1 (Reference)1.17(0.98, 1.44)0.1421.20(1.02, 1.41)0.029 Model 3c1 (Reference)1.03(0.82, 1.28)0.8081.24(1.04, 1.47)0.018OABSS score Model 11 (Reference)1.45(1.31, 1.61)< 0.0011.20(1.09, 1.33)0.001 Model 21 (Reference)1.23(1.09, 1.38)0.0011.18(1.06, 1.32)0.004 Model 31 (Reference)1.11(0.98, 1.25)0.0931.17(1.05, 1.31)0.006With current smokers as the reference groupOAB Model 10.79(0.68, 0.93)0.0031.11(0.91, 1.35)0.3161 (Reference) Model 20.83(0.71, 0.98)0.0290.97(0.78, 1.22)0.8031 (Reference) Model 30.81(0.68, 0.96)0.0180.83(0.66, 1.05)0.1161 (Reference)aModel 1: adjusted for nonebModel 2: adjusted for age, gender, ethnicity, education level, marital status and PIRcModel 3: adjusted for BMI, waist circumference, hypertension, high cholesterol, diabetes, sleep disorder, physical activity level and drinking in addition to Model 2 adjustmentsOAB overactive bladder, OABSS Overactive Bladder Symptom Score, OR odd radio, CI confidence interval Association of smoking status with OAB and OABSS scores aModel 1: adjusted for none bModel 2: adjusted for age, gender, ethnicity, education level, marital status and PIR cModel 3: adjusted for BMI, waist circumference, hypertension, high cholesterol, diabetes, sleep disorder, physical activity level and drinking in addition to Model 2 adjustments OAB overactive bladder, OABSS Overactive Bladder Symptom Score, OR odd radio, CI confidence interval The sensitivity analysis explored the association between ex-smokers and OABSS scores among populations without OAB. A total of 13,272 participants did not meet the diagnostic criteria for OAB and a univariate logistic regression analysis revealed that compared to never smokers, the OR for higher OABSS scores among ex-smokers was 1.41(95% CI: 1.26–1.57, P < 0.001). Other specific baseline information was detailed in Supplementary Table 1. After sequential adjustment for covariates, the positive association between ex-smokers and OAB remained significant in Model 3 (OR = 1.14, 95% CI: 1.02–1.28, P = 0.024) (Table 4). Table 4Association of smoking status with OABSS scores among study populations without OABSmoking statusModel 1aModel 2bModel 3cOR (95% IC)P valueOR (95% IC)P valueOR (95% IC)P valueNever smokers1 (Reference)1 (Reference)1 (Reference)Ex-smokers1.41(1.26, 1.57)< 0.0011.23(1.00, 1.38)0.0011.14(1.02, 1.28)0.024Current smokers1.12(0.99, 1.27)0.0771.13(0.98, 1.29)0.0841.10(0.96, 1.26)0.115aModel 1: adjusted for nonebModel 2: adjusted for age, gender, ethnicity, education level, marital status and PIRcModel 3: adjusted for BMI, waist circumference, hypertension, high cholesterol, diabetes, sleep disorder, physical activity level and drinking in addition to Model 2 adjustmentsOR odds ratio, CI confidence interval, OABSS Overactive Bladder Symptom Score Association of smoking status with OABSS scores among study populations without OAB aModel 1: adjusted for none bModel 2: adjusted for age, gender, ethnicity, education level, marital status and PIR cModel 3: adjusted for BMI, waist circumference, hypertension, high cholesterol, diabetes, sleep disorder, physical activity level and drinking in addition to Model 2 adjustments OR odds ratio, CI confidence interval, OABSS Overactive Bladder Symptom Score To explore the association between daily cigarette consumption and OAB risk, a total of 3,288 current smokers provided complete cigarette smoking data for the past 30 days were included in the further study. Supplementary Table 2 provided the baseline characteristics of current smokers, categorized by quartiles of daily cigarette consumption. Table 5 illustrated a positive association between daily cigarette consumption and OAB. Model 1 indicated that among smokers, for every additional cigarette smoked per day, the risk of OAB increased by 3% (OR = 1.03, 95% CI: 1.01–1.04, P < 0.001) and this association remained significant in Model 3 (OR = 1.03, 95% CI: 1.01–1.04, P = 0.001). Additionally, quartile analysis based on daily cigarette consumption indicated that compared to Light Smokers, Heavy Smokers exhibited a significantly increased risk of OAB in Model 1 (OR = 2.11, 95% CI: 1.45–3.06, P < 0.001), and this association also remained significant in Model 3 (OR = 1.95, 95% CI: 1.23–3.10, P = 0.006). All three models demonstrated a significant dose-response trend with increasing quartiles of daily cigarette consumption. A restricted cubic spline (RCS) (Fig. 2), fitted within the fully adjusted logistic regression model, further confirmed the dose-response relationship (P overall < 0.0001). As daily cigarette consumption increased, the risk of OAB also significantly increased. This relationship was statistically significant, primarily presenting as a linear trend, while the nonlinear component was not significant (P non-linear = 0.8837). Table 5Association of average daily cigarette consumption with OAB among current smokersDaily cigaretteconsumptionModel 1aModel 2bModel 3cOR (95% IC)P valueOR (95% IC)P valueOR (95% IC)P valueContinuous1.03(1.01, 1.04)< 0.0011.03(1.01, 1.05)< 0.0011.03(1.01, 1.04)0.001CategoriesLight1 (Reference)1 (Reference)1 (Reference)Low-Moderate1.29(0.93, 1.78)0.1230.99(0.70, 1.39)0.9400.98(0.67, 1.42)0.899Moderate-High1.51(1.14, 2.00)0.0051.30(0.94, 1.80)0.1121.32(0.93, 1.88)0.115Heavy2.11(1.45, 3.06)< 0.0012.04(1.31, 3.19)0.0031.95(1.23, 3.10)0.006P for trend< 0.001< 0.0010.002aModel 1: adjusted for nonebModel 2: adjusted for age, gender, ethnicity, education level, marital status and PIRcModel 3: adjusted for BMI, waist circumference, hypertension, high cholesterol, diabetes, sleep disorder, physical activity level and drinking in addition to Model 2 adjustmentsOR odds ratio, CI confidence interval, OAB overactive bladder Association of average daily cigarette consumption with OAB among current smokers aModel 1: adjusted for none bModel 2: adjusted for age, gender, ethnicity, education level, marital status and PIR cModel 3: adjusted for BMI, waist circumference, hypertension, high cholesterol, diabetes, sleep disorder, physical activity level and drinking in addition to Model 2 adjustments OR odds ratio, CI confidence interval, OAB overactive bladder RCS analysis of the relationship between average daily cigarette consumption and OAB risk. RCS, Restricted cubic spline; OAB, overactive bladder Subgroup analysis results showed that in most subgroups (Fig. 3), after adjusting for all sociodemographic factors, lifestyle and health risk factors except for the grouping variable, daily cigarette consumption was significantly positively associated with OAB risk, demonstrating the robustness of the results. In all subgroups, the P for interaction did not show significant effects, indicating that the association between daily cigarette consumption and OAB did not differ significantly across subgroups. Subgroup analysis of the association of daily cigarette consumption with OAB among current smokers in Model 3a aModel 3: adjusted for age, gender, ethnicity, education level, marital status, PIR, BMI, waist circumference, hypertension, high cholesterol, diabetes, sleep disorder, physical activity level and drinking b Due to limited data, this model adjusted for gender, education level, PIR, BMI, waist circumference, hypertension, high cholesterol, diabetes and sleep disorder OR, odds ratio; CI, confidence interval; PIR, poverty income ratio; BMI, body mass index; OAB, overactive bladder Discussion In this cross-sectional analysis of NHANES 2011–2018, we found that cigarette smoking was significantly associated with both the presence and symptom burden of OAB. After adjustment for relevant covariates, current smokers showed a higher risk of OAB compared with never smokers, and higher levels of daily cigarette consumption were associated with an increased probability of OAB. Additionally, by focusing on ex-smokers, our study added insight into how smoking cessation relates to OAB-related symptoms in a nationally representative adult population. The pathogenesis of OAB is currently not fully elucidated. Animal studies have shown that ultrastructural changes in the detrusor muscle of OAB bladders disrupt normal smooth muscle electrical coupling, leading to involuntary detrusor contractions [22]. The myogenic hypothesis offers some explanation for OAB, but histological changes in the bladder are not observed in all clinical patients [23]. The neurogenic hypothesis posits that bladder autonomic nerve dysfunction results in idiopathic OAB [24]. Additionally, research indicates that OAB is associated with pathological changes in bladder urothelial cells [25]. Although a comprehensive theoretical basis for the association between smoking and OAB is lacking, nicotine in smoke is currently considered a major risk factor for certain LUTS. Rat studies have demonstrated that intravesical nicotine injection significantly shortens bladder contraction intervals in a dose-dependent manner [26]. Continuous nicotine administration in rats led to upregulation of muscarinic and nicotinic receptors, resulting in detrusor instability and potentially causing LUTS through increased bladder smooth muscle tone [27]. However, no cohort studies have clearly established a positive association between smoking and nocturia alone currently. A prospective cohort study on Danish males indicated no significant association between smoking and nocturia [28]. Two other cross-sectional studies reported that smoking is associated with a lower risk of nocturia, and they attributed the potential mechanism to smoking increasing the release of antidiuretic hormone [29, 30]. Additionally, Blanker et al. found that smoking enhances the circadian rhythm pattern of urine production which helps reduce the presence of nocturia [31]. We hypothesize that nocturia symptoms in OAB should be distinguished from simple nocturnal polyuria. Smoking may exacerbate nocturia symptoms in patients with OAB, but it is not an independent risk factor for nocturia. Further in-depth research is necessary to explore the relationship between smoking and nocturia. Cigarette smoking may influence OAB through indirect mechanisms. A retrospective study conducted in Turkey found that heavy smoking led to elevated serum testosterone levels, which affected prostate symptoms and exacerbated the development of LUTS [32]. Earlier studies have also revealed that polycyclic aromatic hydrocarbons and nicotine in smoke accelerated estrogen metabolism and reduced estrogen receptor expression [33]. Several mechanisms can explain the role of estrogen deprivation in OAB, including increased detrusor contractility via the Rho kinase pathway, altered afferent signaling in the urothelium, and potential symptoms like vaginal dryness and itching in OAB patients, which may contribute to more complex OAB symptoms [34–36]. Certain studies have also revealed the connection between metabolic syndrome and OAB, particularly a positive association between obesity and the presence of OAB [37, 38]. The increased mechanical load in patients with metabolic syndrome stimulated the sensory afferent nerves of the trigone and bladder neck. This process was also influenced by oxidative stress, insulin resistance, and systemic inflammation, which promoted chronic pelvic ischemia and urothelial dysfunction, ultimately leading to the development of complex OAB syndrome. Research has shown that smoking causes insulin resistance and increases the risk of type 2 diabetes [39]. Therefore, cigarette smoking may indirectly promote the presence of OAB, but the mediating effects of hormonal changes and metabolic syndrome require further verification. The association between daily cigarette consumption and OAB appears to be very weak. In individuals with daily smoking habits, the risk of OAB increases by 0.03 for each additional cigarette smoked per day. This conclusion is supported by further subgroup analyses, showing that the impact of smoking does not significantly differ across populations. However, this minor effect has significant public health implications. OAB not only affects patients’ daily lives and social activities but also impacts their emotions, leading to mental health disorders [40]. The prevalence of OAB imposes a substantial healthcare burden on society. Therefore, reducing the number of cigarettes smoked would provide significant social benefits. In exploring the association between different smoking statuses and OAB, we specifically focused on ex-smokers. Our study results indicated that ex-smokers did not have a significantly reduced risk of OAB compared to current smokers. Another cross-sectional study conducted on Japanese females supported our findings [41]. It is worth noting that similar results have been reported on other diseases, where cessation did not significantly reduce the risk of smoking-induced osteoarthritis [42]. However, the temporal direction of these associations and potential recovery trajectories after quitting smoking cannot be determined from our data. On the basis of previous experimental and clinical evidence, we speculated that there is a causal association between smoking and OAB, and smoking cessation may be insufficient to reverse the changes in bladder tissue structure, autonomic nerve damage, and urothelial cell degeneration resulting from long-term smoking. Additionally, tobacco contains abundant aromatic amines and polycyclic aromatic hydrocarbons, which cause DNA damage through single- and double-strand breaks, extensive adduct formation, and base alkylation [43, 44]. However, this does not contradict our encouragement of smoking cessation. Two large cross-sectional studies based on Japanese males and females reported that the risk of LUTS was higher in ex-smokers than in never smokers [41, 45]. These studies relied on online questionnaires for data collection, which may lead to inconsistent results due to differences in reading comprehension and self-reporting bias. More importantly, they neglected the impact of potential covariates. After adjusting for relevant sociodemographic factors, lifestyle and health risk factors, we found that the risk of OAB in ex-smokers was not significantly different from that in never smokers. However, there was a marginal significance between ex-smokers and higher OABSS scores. Through a sensitivity analysis, we further validated that ex-smokers were significantly associated with higher OABSS scores among individuals without OAB. Our findings indicated that, in this cross-sectional analysis, ex-smokers were more likely than never smokers to report more severe nocturia and UUI, particularly among individuals who did not meet the diagnostic criteria for OAB. In other words, ex-smokers did not have a significantly higher prevalence of OAB than never smokers, but they reported a greater burden of nocturia and UUI symptoms that often remained below the threshold for an OAB diagnosis. These associations suggest that a history of smoking is linked to a higher burden of certain LUTS even after smoking cessation. Additionally, our results demonstrated that the risk of OAB and the severity of OAB-related symptoms in ex-smokers are intermediate between those of never smokers and current smokers, suggesting that smoking cessation may be associated with a lower OAB burden than continued smoking and remains a key strategy for the early prevention among smokers. Although the observed effect sizes were modest at the individual level, even small relative increases in risk and symptom scores may translate into a substantial additional burden when extrapolated to the large number of adults who smoke or have a history of smoking. Thus, while some smoking-related changes may be only partially reversible or irreversible, our data still support smoking cessation as a pragmatic, low-cost strategy to limit further OAB-related symptom burden, and underscore the value of routinely incorporating smoking assessment and cessation counselling into the management of patients with OAB or bothersome LUTS. Previous studies on the effects of smoking on LUTS were mainly conducted in Asia [41, 45]. Some existing studies considered anatomical differences in gender and social behavioral patterns across different ages, typically including specific genders or age groups, which limited the generalizability of the results to the entire population [17–19]. Our research data were obtained from a national cohort, and the findings were rooted in the latest epidemiological evidence, ensuring their accuracy and standardization in the current context. Additionally, our study results fully accounted for potential covariates, identifying cigarette smoking as an independent risk factor for OAB and generalizing the findings to the entire adult population for the first time. The shared pathophysiological mechanisms of OAB also support our inference that similar associations may exist in other populations worldwide. On this basis, we proposed hypotheses about the mediating role of various chronic diseases in this context. Furthermore, we conducted, for the first time, an in-depth exploration of ex-smokers by comparing them with never smokers and current smokers to characterize differences in OAB risk and symptom burden. Our findings suggest that ex-smokers reported a higher burden of certain OAB-related symptoms than never smokers, while remaining consistent with the potential health benefits of quitting. This conclusion may provide a reference for the effects of smoking and smoking cessation on the development of other diseases. Our study also has several limitations. First, a methodological limitation is the operational definition of OAB derived from NHANES. Clinically, the diagnosis of OAB is symptom-based and lacks a universally accepted gold standard, and our adapted OABSS score is constrained by the content of the NHANES questionnaires. In particular, NHANES does not include specific urgency and daytime frequency questions, so the derived score cannot fully match the International Continence Society (ICS) definition or the original OABSS. Moreover, although our scoring scheme follows approaches used in previous NHANES-based studies, it has not itself been formally validated as a diagnostic tool. Taken together, these issues mean that some degree of misclassification of OAB is unavoidable. Additionally, reliance on nocturia and urgency urinary incontinence items and their overlap with other LUTS may blur the distinction between OAB and other lower urinary tract conditions and could lead to over- or underestimation of the true prevalence of OAB. Second, due to the stratified sampling design of NHANES, some potentially relevant covariates are only available from laboratory testing. Including these variables would substantially reduce the sample size and compromise the representativeness of the study population. To avoid insufficient sample size and unstable estimates, we therefore chose to exclude laboratory-dependent variables. Participants might also use other tobacco products that were not fully captured in our analysis, which could further complicate the interpretation of smoking-related effects. Although we included as many available covariates as possible to enhance the validity and reliability of the results, residual confounding by unmeasured or imprecisely measured factors cannot be ruled out. In addition, regional differences in social behaviors and healthcare systems across countries may influence the early diagnosis and management of OAB, which may in turn affect the generalizability of our findings and the observed strength of its association with smoking. Third, the cross-sectional design of our study does not allow us to determine the temporal relationship between smoking status, including the duration after quitting smoking, and OAB. In real-life settings, individuals with OAB or bothersome LUTS may be more likely to quit smoking. This potential reverse causation could bias our comparisons and, in particular, may lead to an overestimation of OAB prevalence and symptom burden among ex-smokers relative to never smokers in this analysis. Future multinational and cross-cultural longitudinal studies are warranted to validate our findings, to clarify the temporal and potentially causal relationships between smoking, smoking cessation, and OAB, and to integrate mechanistic investigations that may help elucidate the underlying biological pathways and provide global evidence for incorporating smoking cessation into OAB prevention and management strategies. Conclusion This cross-sectional research established that cigarette smoking was independently associated with both the presence and a greater symptom burden of OAB. Ex-smokers showed intermediate levels of OAB risk and OAB-related symptoms between never smokers and current smokers, suggesting that a history of smoking is associated with an intermediate level of OAB-related symptom burden after quitting. These findings support the clinical relevance of smoking history, including current and past smoking, in the evaluation and management of OAB, and highlight the need for longitudinal and mechanistic studies to clarify the causal and potentially reversible effects of smoking and smoking cessation on OAB. Supplementary Information Supplementary Material 1. Acknowledgements All data were sourced from the NHANES database, managed by the Centers for Disease Control and Prevention, and the authors extend their sincere gratitude. Abbreviations Overactive bladder Lower urinary tract syndrome Overactive Bladder Symptom Score, a questionnaire Odds ratio Confidence interval National Health and Nutrition Examination Survey Centers for Disease Control and Prevention Urgency urinary incontinence Physical activity metabolic equivalent National center for health statistics Body mass index Metabolic equivalent International Continence Society Authors’ contributions Weibo Wang: Writing – original draft, review & editing, Software, Conceptualization, Visualization. Supeng Tai: Software, Methodology. Xi Cheng: Conceptualization, Validation. Junyue Tao: Supervision. Lexing Yang: Writing – review and editing. Jun Zhou: Funding acquisition. Funding This work was supported by the Health committee project of Anhui Province in China (AHWJ2023BAc10007) and Outstanding Scientific Research and Innovation Team for Male Genitourinary Diseases in Anhui Provincial Universities (2022AH010071). Data availability All data generated or analyzed during this study are included in this published article. Additional data are available from the corresponding author on reasonable request. Declarations Ethics approval and consent to participate The NHANES protocol was approved by the Ethics Review Board of the National Center for Health Statistics, and this study was exempt from additional ethical approval. Consent for publication Each participant in this study provided informed consent. Competing interests The authors declare no competing interests. Footnotes Publisher’s Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. Weibo Wang and Supeng Tai contributed equally to this work. References Associated Data Supplementary Materials Supplementary Material 1. Data Availability Statement All data generated or analyzed during this study are included in this published article. Additional data are available from the corresponding author on reasonable request.